Lysine analogues- chloromethyl ketones

Already in 1981 a medicinal chemist at Bayer in Wuppertal, Germany [Gerd Reinhardt,  Ann. N.Y. Acad. Sci. 1981, 370, 836.] designed a series of direct acting Factor XIIIa blockers. According to the author the molecule combines the substrate amine architecture (Lysine co-substrate) with the chemical reactivity of the sulfhydryl reagent (active site cysteine attacking the chloromethyl ketone). The compound inhibits at least tissue transglutaminase as well.

Lysine analogues reaction machanism


Art. No.
Name
Quantity
Price
C094 Tosyl-ε-aminopentyl-CMK
1 mg
415 €
C095 Dansyl-ε-aminopentyl-CMK
1 mg
415 €

  • News  

    • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Blog

  • Events  

    • Transglutaminases in Medicine

      03.08.2017 - 05.08.2017
      Debrecen, Hungary

    • 15th Congress on Amino Acids, Peptides and Proteins

      07.08.2017 - 11.08.2017
      Vienna, Austria

    • 17th International Celiac Disease Symposium

      08.09.2017 - 10.09.2017
      New Delhi, India

    • NLSDays 2017

      12.09.2017 - 14.09.2017
      Malmö, Sweden

    • BIO-Europe

      06.11.2017 - 08.11.2017
      Berlin, Germany

    • MEDICA

      13.11.2017 - 16.11.2017
      Düsseldorf, Germany

    • Gordon Research Conference on: Transglutaminases in Human Disease Processes

      16.06.2018 - 17.06.2018
      Les Diablerets, Switzerland